Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aroa Biosurgery Ltd ( (AU:ARX) ) has shared an announcement.
Aroa Biosurgery Limited announced the cessation of John Pinion as a director, effective October 31, 2025. This update includes details of his interests in the company’s securities, which consist of fully paid ordinary shares and options. The announcement is part of the company’s compliance with ASX listing rules and may have implications for its governance and strategic direction.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Limited operates in the biosurgery industry, focusing on developing and manufacturing regenerative tissue products. The company provides solutions for soft tissue repair and complex wounds, aiming to enhance healing and improve patient outcomes.
Average Trading Volume: 270,603
Technical Sentiment Signal: Buy
Current Market Cap: A$267.4M
Find detailed analytics on ARX stock on TipRanks’ Stock Analysis page.